Neuromyelitis Optica Spectrum Disorder

Ophthalmology
5
Pipeline Programs
4
Companies
6
Clinical Trials
3 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
267%
Small Molecule
133%
+ 3 programs with unclassified modality

On Market (1)

Approved therapies currently available

Roche
ENSPRYNGApproved
satralizumab
Roche
injection2020

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Roche
RocheSTAVANGER NORWAY, Norway
2 programs
1
1
Satralizumab 120 mgPhase 4
SatralizumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT05199688Recruiting8Est. Sep 2029
CP
Chugai PharmaJapan - Tokyo
1 program
1
Satralizumab 120 mgPhase 41 trial
Active Trials
NCT05269667Terminated4Est. Oct 2023
Amgen
AmgenTHOUSAND OAKS, CA
2 programs
1
InebilizumabPhase 2Monoclonal Antibody1 trial
UPLIZNAN/A2 trials
Active Trials
NCT06590051Available
NCT05909761Recruiting60Est. Oct 2032
NCT05549258Recruiting15Est. Apr 2027
InnoCare
InnoCareChina - Beijing
1 program
OrelabrutinibN/ASmall Molecule1 trial
Active Trials
NCT05284175Unknown23Est. Aug 2023

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Chugai PharmaSatralizumab 120 mg
RocheSatralizumab
AmgenInebilizumab
AmgenUPLIZNA
InnoCareOrelabrutinib

Clinical Trials (6)

Total enrollment: 110 patients across 6 trials

NCT05269667Chugai PharmaSatralizumab 120 mg

A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention

Start: Aug 2022Est. completion: Oct 20234 patients
Phase 4Terminated
NCT05199688RocheSatralizumab

A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

Start: Mar 2026Est. completion: Sep 20298 patients
Phase 3Recruiting
NCT05549258AmgenInebilizumab

Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder

Start: Jul 2023Est. completion: Apr 202715 patients
Phase 2Recruiting
NCT06590051AmgenUPLIZNA

AMG 335 Expanded Access Program for IgG4-Related Disease

N/AAvailable
NCT05909761AmgenUPLIZNA

Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy

Start: Apr 2026Est. completion: Oct 203260 patients
N/ARecruiting
NCT05284175InnoCareOrelabrutinib

A Study of Orelabrutinib in Patients With AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder

Start: Apr 2022Est. completion: Aug 202323 patients
N/AUnknown

Related Jobs in Ophthalmology

Lead Data Manager

Genomics
Remote
4h ago

Cleanroom and Laboratory Technician

SAB BIO
4h ago

Product Specialist

Johnson & Johnson
Hangzhou, Zhejiang, China
20h ago

BM 喀什 PSR HY

Johnson & Johnson
Urumqi, Xinjiang, China
20h ago

Site Delivery Leader MLL

Johnson & Johnson
Gent, East Flanders, Belgium
20h ago

Clinical Operations Manager

Johnson & Johnson
Irvine, California, United States of America
20h ago
$117K - $201K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
3 actively recruiting trials targeting 110 patients
4 companies competing in this space

Related Indications

Myopia(127)Cataract(116)Open-Angle Glaucoma(102)Glaucoma(92)Dry Eye(74)Age-Related Macular Degeneration(73)Dry Eye Disease(43)Neovascular Age-related Macular Degeneration(40)Macular Degeneration(37)Diabetic Retinopathy(25)